Ammar Almaaytah

1.4k total citations
54 papers, 1.1k citations indexed

About

Ammar Almaaytah is a scholar working on Molecular Biology, Microbiology and Immunology. According to data from OpenAlex, Ammar Almaaytah has authored 54 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 21 papers in Microbiology and 10 papers in Immunology. Recurrent topics in Ammar Almaaytah's work include Antimicrobial Peptides and Activities (21 papers), Biochemical and Structural Characterization (13 papers) and Biosimilars and Bioanalytical Methods (7 papers). Ammar Almaaytah is often cited by papers focused on Antimicrobial Peptides and Activities (21 papers), Biochemical and Structural Characterization (13 papers) and Biosimilars and Bioanalytical Methods (7 papers). Ammar Almaaytah collaborates with scholars based in Jordan, Saudi Arabia and Poland. Ammar Almaaytah's co-authors include Qosay Al‐Balas, Tareq L. Mukattash, Mohammad A. Hassan, Nizar A. Al‐Shar’i, Shadi Tarazi, Nizar M. Mhaidat, Chris Shaw, Mei Zhou, Tianbao Chen and Lei Wang and has published in prestigious journals such as Molecules, Pharmaceutical Research and Current Pharmaceutical Design.

In The Last Decade

Ammar Almaaytah

51 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ammar Almaaytah Jordan 20 626 483 243 91 86 54 1.1k
Karen Ingraham United States 17 823 1.3× 194 0.4× 184 0.8× 109 1.2× 227 2.6× 22 1.4k
George P. Dinos Greece 18 677 1.1× 97 0.2× 149 0.6× 128 1.4× 144 1.7× 33 1.2k
Shankar Thangamani United States 23 762 1.2× 246 0.5× 34 0.1× 359 3.9× 99 1.2× 48 1.7k
Zulfiqar Ahmad United States 25 1.1k 1.7× 152 0.3× 77 0.3× 110 1.2× 77 0.9× 69 1.6k
Ayesha Rahman United Kingdom 13 428 0.7× 81 0.2× 70 0.3× 99 1.1× 159 1.8× 25 850
Paul Miller United States 23 1.5k 2.4× 123 0.3× 637 2.6× 101 1.1× 187 2.2× 40 2.8k
Mohammad Abul Kalam Azad Australia 21 409 0.7× 186 0.4× 63 0.3× 95 1.0× 485 5.6× 65 1.6k
Yongxin Jin China 21 870 1.4× 92 0.2× 408 1.7× 40 0.4× 89 1.0× 96 1.5k
Timothy R. Kane Canada 5 287 0.5× 71 0.1× 63 0.3× 88 1.0× 165 1.9× 5 797
Roberta J. Melander United States 16 345 0.6× 111 0.2× 39 0.2× 174 1.9× 91 1.1× 36 757

Countries citing papers authored by Ammar Almaaytah

Since Specialization
Citations

This map shows the geographic impact of Ammar Almaaytah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ammar Almaaytah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ammar Almaaytah more than expected).

Fields of papers citing papers by Ammar Almaaytah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ammar Almaaytah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ammar Almaaytah. The network helps show where Ammar Almaaytah may publish in the future.

Co-authorship network of co-authors of Ammar Almaaytah

This figure shows the co-authorship network connecting the top 25 collaborators of Ammar Almaaytah. A scholar is included among the top collaborators of Ammar Almaaytah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ammar Almaaytah. Ammar Almaaytah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Almaaytah, Ammar, et al.. (2023). Pharmaco-epigenetics: Histone modification and personalized medicine. Pharmacia. 70(2). 337–349. 2 indexed citations
3.
Almaaytah, Ammar, et al.. (2023). The design and functional characterization of a novel hybrid antimicrobial peptide from Esculentin-1a and melittin. Pharmacia. 70(1). 161–170. 3 indexed citations
4.
Almaaytah, Ammar. (2022). ANTIMICROBIAL PEPTIDES AS POTENTIAL THERAPEUTICS: ADVANTAGES, CHALLENGES AND RECENT ADVANCES. FARMACIA. 70(6). 991–1003. 2 indexed citations
5.
Almaaytah, Ammar, et al.. (2021). Immunodiagnosis of cattle fascioliasis using a 27 kDa Fasciola gigantica antigen. Veterinary World. 14(8). 2097–2101. 2 indexed citations
6.
Almaaytah, Ammar & Ali Salama. (2020). Acceptance of COVID-19 vaccination among jordanian adults: a cross sectional study. Systematic Reviews in Pharmacy. 11(11). 1291–1297. 4 indexed citations
7.
Almaaytah, Ammar. (2020). <p>Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa</p>. ClinicoEconomics and Outcomes Research. Volume 12. 527–534. 7 indexed citations
8.
Al‐Balas, Qosay, et al.. (2019). Multi-Armed 1,2,3-Selenadiazole and 1,2,3-Thiadiazole Benzene Derivatives as Novel Glyoxalase-I Inhibitors. Molecules. 24(18). 3210–3210. 8 indexed citations
9.
Almaaytah, Ammar, et al.. (2019). The Design and Anticancer Activity of a Citropin1.1 Hybrid Peptide with Selective Activity Against Highly Invasive Metastatic Cell Lines. International Journal of Research in Pharmaceutical Sciences. 10(4). 3544–3553. 1 indexed citations
10.
Almaaytah, Ammar, Qosay Al‐Balas, & Karem H. Alzoubi. (2018). In vivo antimicrobial activity of the hybrid peptide H4: a follow-up study. Infection and Drug Resistance. Volume 11. 1383–1386. 6 indexed citations
11.
Al‐Balas, Qosay, et al.. (2018). Design, Synthesis and Biological Evaluation of Potential Novel Zinc Binders Targeting Human Glyoxalase-I; A Validated Target for Cancer Treatment. Jordan Journal of Pharmaceutical Sciences. 11(1). 4 indexed citations
12.
Almaaytah, Ammar, et al.. (2018). Antimicrobial and Antibiofilm Activity of UP-5, an Ultrashort Antimicrobial Peptide Designed Using Only Arginine and Biphenylalanine. Pharmaceuticals. 11(1). 3–3. 42 indexed citations
13.
14.
Almaaytah, Ammar, et al.. (2018). Hybridization and antibiotic synergism as a tool for reducing the cytotoxicity of antimicrobial peptides. Infection and Drug Resistance. Volume 11. 835–847. 36 indexed citations
15.
Almaaytah, Ammar, et al.. (2017). Development of novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial and antibiofilm activities against multidrug-resistant bacteria. Drug Design Development and Therapy. Volume 11. 3159–3170. 87 indexed citations
16.
Al‐Balas, Qosay, Mohammad A. Hassan, Nizar A. Al‐Shar’i, Tamam El‐Elimat, & Ammar Almaaytah. (2017). Computational and experimental exploration of the structure–activity relationships of flavonoids as potent glyoxalase‐I inhibitors. Drug Development Research. 79(2). 58–69. 17 indexed citations
17.
Mukattash, Tareq L., et al.. (2016). Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: A descriptive study from Jordan. Pharmacy Practice. 14(3). 725–725. 19 indexed citations
18.
Almaaytah, Ammar, et al.. (2014). Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. Pharmaceuticals. 7(5). 502–516. 40 indexed citations
19.
Al‐Balas, Qosay, Haneen Amawi, Mohammad A. Hassan, et al.. (2013). Virtual Lead Identification of Farnesyltransferase Inhibitors Based on Ligand and Structure-Based Pharmacophore Techniques. Pharmaceuticals. 6(6). 700–715. 19 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Ingraham Breakdown of academic impact, for papers by George P. Dinos Breakdown of academic impact, for papers by Shankar Thangamani Breakdown of academic impact, for papers by Zulfiqar Ahmad Breakdown of academic impact, for papers by Ayesha Rahman Breakdown of academic impact, for papers by Paul Miller Breakdown of academic impact, for papers by Mohammad Abul Kalam Azad Breakdown of academic impact, for papers by Yongxin Jin Breakdown of academic impact, for papers by Timothy R. Kane Breakdown of academic impact, for papers by Roberta J. Melander
Rankless by CCL
2026